{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:29:06Z","timestamp":1790836146330,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016949","name":"Tenax Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jacbts.2021.07.012","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T15:46:56Z","timestamp":1638373616000},"page":"70-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Translation of New and Emerging Therapies for Genetic Cardiomyopathies"],"prefix":"10.1016","volume":"7","author":[{"given":"Adam S.","family":"Helms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.jacbts.2021.07.012_bib1","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.mayocp.2014.01.025","article-title":"Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy","volume":"89","author":"Bos","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacbts.2021.07.012_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2017.79","article-title":"Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup","volume":"20","author":"Ko","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib4","first-page":"3461","article-title":"Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes","volume":"38","author":"Walsh","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2021.07.012_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002460","article-title":"Evaluating the clinical validity of hypertrophic cardiomyopathy genes","volume":"12","author":"Ingles","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib6","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/eurheartj\/ehab424","article-title":"Alpha-protein kinase 3 (ALPK3)-truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy.","volume":"42","author":"Lopes","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.jacbts.2021.07.012_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.116.309396","article-title":"Dilated cardiomyopathy: genetic determinants and mechanisms","volume":"121","author":"McNally","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2021.07.012_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","article-title":"Dilated cardiomyopathy: the complexity of a diverse genetic architecture","volume":"10","author":"Hershberger","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib9","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2016.08.058","article-title":"Long-term arrhythmic and nonarrhythmic outcomes of lamin A\/C mutation carriers","volume":"68","author":"Kumar","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib10","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.119.044934","article-title":"Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy","volume":"141","author":"Smith","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/hrt.2010.205542","article-title":"Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy","volume":"97","author":"Lehrke","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jacbts.2021.07.012_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005371","article-title":"Regional variation in RBM20 causes a highly penetrant arrhythmogenic cardiomyopathy","volume":"12","author":"Parikh","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.jacbts.2021.07.012_bib13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamacardio.2021.1106","article-title":"Association of left ventricular systolic dysfunction among carriers of truncating variants in filamin C with frequent ventricular arrhythmia and end-stage heart failure","volume":"6","author":"Akhtar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.jacbts.2021.07.012_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003273","article-title":"An international evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy (ARVC) using the ClinGen framework","volume":"14","author":"James","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001966","article-title":"Whole-exome sequencing reveals GATA4 and PTEN mutations as a potential digenic cause of left ventricular noncompaction","volume":"11","author":"Tang","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"2","key":"10.1016\/j.jacbts.2021.07.012_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jacbts.2021.07.012_bib18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","article-title":"Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect","volume":"53","author":"Tadros","year":"2021","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.jacbts.2021.07.012_bib19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehaa1061","article-title":"The year in cardiovascular medicine 2020: heart failure and cardiomyopathies","volume":"42","author":"Bueno","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2021.07.012_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2017.02.008","article-title":"The design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial","volume":"187","author":"Ho","year":"2017","journal-title":"Am Heart J"},{"issue":"6372","key":"10.1016\/j.jacbts.2021.07.012_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jacbts.2021.07.012_bib25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: poised at the clinical crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jacbts.2021.07.012_bib26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0091-679X(08)60385-4","article-title":"Adenovirus-mediated myofilament gene transfer into adult cardiac myocytes","volume":"52","author":"Westfall","year":"1997","journal-title":"Methods Cell Biol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-9139-6_2","article-title":"Design of AAV vectors for delivery of large or multiple transgenes","volume":"1950","author":"Patel","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib30","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum Mol Genet"},{"issue":"suppl 1","key":"10.1016\/j.jacbts.2021.07.012_bib31","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0960-8966(02)00078-0","article-title":"Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin","volume":"12","author":"Scott","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jacbts.2021.07.012_bib32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2010.94","article-title":"Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs","volume":"18","author":"Kornegay","year":"2010","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.jacbts.2021.07.012_bib33","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jacbts.2021.07.012_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2021.07.012_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.omtm.2017.01.003","article-title":"Effective depletion of pre-existing anti-AAV antibodies requires broad immune targeting","volume":"4","author":"Velazquez","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.jacbts.2021.07.012_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jacbts.2021.07.012_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.118.036965","article-title":"Allele-specific silencing ameliorates restrictive cardiomyopathy attributable to a human myosin regulatory light chain mutation","volume":"140","author":"Zaleta-Rivera","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib39","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.120.051836","article-title":"Suppression-replacement KCNQ1 gene therapy for type 1 long QT syndrome","volume":"143","author":"Dotzler","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib40","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacbts.2021.07.012_bib42","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","article-title":"The CRISPR tool kit for genome editing and beyond","volume":"9","author":"Adli","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacbts.2021.07.012_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.jacbts.2021.07.012_bib44","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2021.07.012_bib45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In\u00a0vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jacbts.2021.07.012_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jacbts.2021.07.012_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells","volume":"5","author":"Min","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.jacbts.2021.07.012_bib48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR correction of Duchenne muscular dystrophy","volume":"70","author":"Min","year":"2019","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib49","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jacbts.2021.07.012_bib50","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.3390\/molecules25122866","article-title":"Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy","volume":"25","author":"Wahane","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jacbts.2021.07.012_bib51","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ejhg.2014.211","article-title":"Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects","volume":"23","author":"Wessels","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12265-011-9266-2","article-title":"How do mutations in contractile proteins cause the primary familial cardiomyopathies?","volume":"4","author":"Marston","year":"2011","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jacbts.2021.07.012_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187948","article-title":"Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage","volume":"12","author":"Viswanathan","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jacbts.2021.07.012_bib54","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","article-title":"Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)","volume":"138","author":"O\u2019Connor","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacbts.2021.07.012_bib56","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib57","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: a potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik","year":"2011","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.jacbts.2021.07.012_bib58","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/ejhf.1933","article-title":"Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial","volume":"22","author":"Voors","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2021.07.012_bib59","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1038\/s41467-018-06193-2","article-title":"Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke","volume":"9","author":"Woody","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jacbts.2021.07.012_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A\u00a0small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jacbts.2021.07.012_bib62","doi-asserted-by":"crossref","first-page":"E7486","DOI":"10.1073\/pnas.1720342115","article-title":"Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin","volume":"115","author":"Rohde","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2021.07.012_bib63","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2021.07.012_bib64","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib65","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib66","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8 suppl","key":"10.1016\/j.jacbts.2021.07.012_bib67","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.cardfail.2019.07.225","article-title":"A\u00a0first in human study of the selective cardiac myosin inhibitor, CK-3773274","volume":"25","author":"Robertson","year":"2019","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacbts.2021.07.012_bib68","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/CIRCRESAHA.110.223842","article-title":"Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor","volume":"111","author":"Moore","year":"2012","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.jacbts.2021.07.012_bib70","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202012662","article-title":"Complexity in genetic cardiomyopathies and new approaches for mechanism-based precision medicine","volume":"153","author":"Greenberg","year":"2021","journal-title":"J\u00a0Gen Physiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib71","doi-asserted-by":"crossref","first-page":"17831","DOI":"10.1073\/pnas.1910962116","article-title":"Disrupted mechanobiology links the molecular and cellular phenotypes in familial dilated cardiomyopathy","volume":"116","author":"Clippinger","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2021.07.012_bib72","doi-asserted-by":"crossref","first-page":"H705","DOI":"10.1152\/ajpheart.2001.280.2.H705","article-title":"Ca2+ activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T","volume":"280","author":"Chandra","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib73","first-page":"145","article-title":"The calcium sensitizer drug MCI-154 binds the structural C-terminal domain of cardiac troponin C","volume":"16","author":"Li","year":"2018","journal-title":"Biochem Biophys Rep"},{"issue":"suppl 5","key":"10.1016\/j.jacbts.2021.07.012_bib74","first-page":"61","article-title":"[Calcium sensitizer agents in heart failure therapy]","volume":"65","author":"Iwama","year":"2007","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.jacbts.2021.07.012_bib75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.abb.2015.03.015","article-title":"Calcium desensitizer catechin reverses diastolic dysfunction in mice with restrictive cardiomyopathy","volume":"573","author":"Zhang","year":"2015","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jacbts.2021.07.012_bib76","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib77","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/3-540-29717-0_16","article-title":"Chemical chaperones: mechanisms of action and potential use","volume":"172","author":"Papp","year":"2006","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib78","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","article-title":"Inhibiting transthyretin amyloid fibril formation via protein stabilization","volume":"93","author":"Miroy","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2021.07.012_bib79","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2021.07.012_bib80","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jacbts.2021.07.012_bib81","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/10600280211000351","article-title":"Transthyretin amyloid cardiomyopathy-current and future therapies","volume":"55","author":"Yadav","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacbts.2021.07.012_bib82","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/CIRCULATIONAHA.109.879510","article-title":"Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy","volume":"121","author":"Gianni","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib83","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jacc.2015.01.031","article-title":"Cofilin-2 phosphorylation and sequestration in myocardial aggregates: novel pathogenetic mechanisms for idiopathic dilated cardiomyopathy","volume":"65","author":"Subramanian","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacbts.2021.07.012_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13504","article-title":"The long and winding road to target protein misfolding in cardiovascular diseases","volume":"51","author":"Diteepeng","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacbts.2021.07.012_bib85","doi-asserted-by":"crossref","first-page":"11866","DOI":"10.1073\/pnas.1900437116","article-title":"Why haploinsufficiency persists","volume":"116","author":"Morrill","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2021.07.012_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001154","article-title":"Characterising and predicting haploinsufficiency in the human genome","volume":"6","author":"Huang","year":"2010","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/CIRCRESAHA.109.202440","article-title":"Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency","volume":"105","author":"Marston","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2021.07.012_bib88","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00424-018-2226-9","article-title":"Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy","volume":"471","author":"Glazier","year":"2019","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jacbts.2021.07.012_bib89","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yjmcc.2018.12.003","article-title":"MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy","volume":"127","author":"O\u2019Leary","year":"2019","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib90","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1126\/science.aaa5458","article-title":"Heart disease. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy","volume":"349","author":"Hinson","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jacbts.2021.07.012_bib91","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/s41431-018-0169-4","article-title":"Frequency of genetic variants associated with arrhythmogenic right ventricular cardiomyopathy in the genome aggregation database","volume":"26","author":"Hall","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib92","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI94310","article-title":"Loss-of-function mutations in co-chaperone BAG3 destabilize small HSPs and cause cardiomyopathy","volume":"127","author":"Fang","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacbts.2021.07.012_bib93","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ajhg.2011.01.016","article-title":"Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy","volume":"88","author":"Norton","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib94","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2018.08.2171","article-title":"Genetic basis of severe childhood-onset cardiomyopathies","volume":"72","author":"Vasilescu","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib95","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/1765","article-title":"A\u00a0missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy","volume":"20","author":"Vicart","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib96","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2018.08.2181","article-title":"Dilated cardiomyopathy caused by BLC2-associated athanogene 3 (BAG3) mutations","volume":"72","author":"Dominguez","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib97","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1074\/jbc.TM118.002813","article-title":"Inhibitors and chemical probes for molecular chaperone networks","volume":"294","author":"Gestwicki","year":"2019","journal-title":"J\u00a0Biol Chem"},{"issue":"11","key":"10.1016\/j.jacbts.2021.07.012_bib98","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99319","article-title":"HSC70 is a chaperone for wild-type and mutant cardiac myosin binding protein C","volume":"3","author":"Glazier","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacbts.2021.07.012_bib99","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133782","article-title":"Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy","volume":"5","author":"Helms","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacbts.2021.07.012_bib100","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.117.311002","article-title":"Cardiovascular Metabolomics","volume":"122","author":"McGarrah","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2021.07.012_bib101","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","article-title":"Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial","volume":"4","author":"Coats","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib102","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/science.abc8861","article-title":"Comprehensive quantification of fuel use by the failing and nonfailing human heart","volume":"370","author":"Murashige","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jacbts.2021.07.012_bib103","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","article-title":"Implications of altered ketone metabolism and therapeutic ketosis in heart failure","volume":"141","author":"Selvaraj","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib104","doi-asserted-by":"crossref","unstructured":"Nikolic M, Zivkovic V, Jovic JJ, et\u00a0al. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Fail Rev. Published online February 3, 2021. https:\/\/doi.org\/10.1007\/s10741-021-10079-9","DOI":"10.1007\/s10741-021-10079-9"},{"key":"10.1016\/j.jacbts.2021.07.012_bib105","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.115.020086","article-title":"Genotype-dependent and -independent calcium signaling dysregulation in human hypertrophic cardiomyopathy","volume":"134","author":"Helms","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.07.012_bib106","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10863-005-9474-z","article-title":"SERCA2a in heart failure: role and therapeutic prospects","volume":"37","author":"Gianni","year":"2005","journal-title":"J\u00a0Bioenerg Biomembr"},{"key":"10.1016\/j.jacbts.2021.07.012_bib107","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1073\/pnas.95.9.5251","article-title":"Modulation of ventricular function through gene transfer in\u00a0vivo","volume":"95","author":"Hajjar","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2021.07.012_bib108","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/gt.2008.120","article-title":"Recirculating cardiac delivery of AAV2\/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals","volume":"15","author":"Byrne","year":"2008","journal-title":"Gene Therapy"},{"key":"10.1016\/j.jacbts.2021.07.012_bib109","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2021.07.012_bib110","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1172\/JCI27751","article-title":"Suppression of canonical Wnt\/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy","volume":"116","author":"Garcia-Gras","year":"2006","journal-title":"J\u00a0Clin Invest"},{"issue":"17","key":"10.1016\/j.jacbts.2021.07.012_bib111","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.3390\/ijms21176320","article-title":"Established and emerging mechanisms in the pathogenesis of arrhythmogenic cardiomyopathy: a multifaceted disease","volume":"21","author":"Gao","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2021.07.012_bib112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.yjmcc.2013.10.019","article-title":"Myofibroblasts: trust your heart and let fate decide","volume":"70","author":"Davis","year":"2014","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib113","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jacbts.2021.07.012_bib114","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1505517","article-title":"Shared genetic\u00a0predisposition in peripartum and dilated cardiomyopathies","volume":"374","author":"Ware","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.07.012_bib115","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCULATIONAHA.120.052395","article-title":"Genetic and phenotypic landscape of peripartum cardiomyopathy","volume":"143","author":"Goli","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacbts.2021.07.012_bib116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamacardio.2019.4268","article-title":"Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy","volume":"5","author":"Fumagalli","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacbts.2021.07.012_bib117","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2017.2503","article-title":"Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial","volume":"317","author":"Saberi","year":"2017","journal-title":"JAMA"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X21002643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X21002643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:24:39Z","timestamp":1762820679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X21002643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2452302X21002643"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2021.07.012","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translation of New and Emerging Therapies for Genetic Cardiomyopathies","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2021.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}